FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus

The FDA has granted Fast Track designation to EG-501 (Evergreen Therapeutics), an investigational oral therapy for cognitive impairment in adults with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study. According to a company announcement, the designation comes after the therapy demonstrated clinically meaningful improvements in objective neuropsychological function among patients with lupus-related cognitive dysfunction.¹

Currently, there are no approved therapies specifically targeting cognitive impairment in NPSLE, highlighting a significant unmet need for this patient population. The Fast Track designation, which is intended to accelerate the development and review of therapies for serious conditions, represents an important regulatory step for EG-501 as Evergreen looks to build on its promising phase 2 findings.

EG-501 ClearMEMory phase 2 trial design and cognitive outcomes

The 12-week, multicenter, randomized, double-blind, placebo-controlled ClearMEMory trial evaluated the safety and efficacy of EG-501 in 56 adults with lupus and cognitive dysfunction. Participants were identified using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and enrolled across 3 clinical sites: Vanderbilt Health Main Campus, Cleveland Clinic, and the University of Texas Health Science Center at Houston.²

At the conclusion of the study, patients treated with EG-501 demonstrated significantly greater improvements in objective cognitive performance compared with those receiving placebo, as measured by changes in the RBANS Total Scale Index score. According to a Vanderbilt University Medical Center news release, the findings suggest that EG-501 may offer a potential treatment option for cognitive impairment associated with lupus.

In its Fast Track announcement, Evergreen characterized the findings as clinically meaningful improvements in objective neuropsychological function, although specific effect sizes and P values were not provided in either source document. The study was funded by Evergreen Therapeutics, the Kleberg Foundation, and an NIH Clinical and Translational Science Award.^1,2

EG-501 mechanism, investigator comment, and phase 3 plans in NPSLE

EG-501 is an investigational oral small-molecule therapy that acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, reducing activity at the receptor. Preliminary research has suggested that the agent may help reduce neuroinflammation and provide neuroprotective effects, offering a potential approach to addressing cognitive dysfunction in patients with NPSLE.

Leslie Crofford, MD, principal investigator of ClearMEMory and former director of the Division of Rheumatology and Immunology at Vanderbilt Health, expressed enthusiasm about the findings, stating, “I am very optimistic about these results.”²

Similarly, Tom Du, MD, PhD, chief executive officer of Evergreen Therapeutics, welcomed the regulatory designation, noting that the company was “very pleased to receive Fast Track designation for our EG-501 program.” Du added that Evergreen looks forward to working closely with the FDA to advance the therapy toward patients as quickly as possible.¹

Building on the positive phase 2 results and recent Fast Track designation, Evergreen is preparing a larger phase 3 trial to further evaluate EG-501 and confirm its potential benefits in patients with NPSLE-related cognitive impairment. Although the company has outlined plans for the next stage of clinical development, a timeline for initiating the phase 3 program has not yet been announced.²

REFERENCES
1. Evergreen Therapeutics. Evergreen Therapeutics receives FDA Fast Track designation for EG-501 cognitive impairment associated with neuropsychiatric SLE. Published October 13, 2026. Accessed October 15, 2026. https://www.prnewswire.com/news-releases/evergreen-therapeutics-receives-fda-fast-track-designation-for-eg-501-cognitive-impairment-associated-with-neuropsychiatric-sle-302906957.html
2. Vanderbilt University Medical Center. Drug lifts “brain fog” from lupus patients: clinical trial. Published April 20, 2026. Accessed October 15, 2026. https://news.vumc.org/2026/04/20/drug-lifts-brain-fog-from-lupus-patients-clinical-trial/